


### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the application. Please amend Claims 36, 37, 38, and 40 and cancel Claims 43, 65, and 70-79 without prejudice or disclaimer. Deletions appear in ~~striketrough font~~, and additions are underlined.

#### Listing of the claims

1-35. (Canceled)

36. (Currently Amended) A compound of formula (I)



wherein

- R1 represents a group chosen from phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, benzyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl, and thiophen-3-ylmethyl;

- R2 represents a group chosen from optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated cycloalkylmethyl, phenyl, benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl, thiophen-3-ylmethyl, pyridyl, and pyridylmethyl; wherein the carbocyclic moieties in the cycloalkyl, cycloalkylmethyl,

phenyl, benzyl or phenethyl groups are optionally bridged or fused to another saturated, unsaturated or aromatic carbocyclic moiety or to a cyclic moiety comprising carbon atoms and 1 or 2 oxygen atoms;

wherein the cyclic groups present in R1 and R2 are optionally substituted by one, two or three, which may be identical or different, substituents chosen from halogen; straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower alkoxy; -SH; straight or branched optionally substituted lower alkylthio; nitro; cyano; -NR'R"; -CO<sub>2</sub>R'; -C(O)-NR'R"; -N(R''')C(O)-R'; and -N(R''')-C(O)NR'R"; wherein R', R'' and R''', which may be identical or different, are each independently chosen from a hydrogen atom, and a straight or branched, optionally substituted lower alkyl group, or R' and R'' together with the atom to which they are attached form a cyclic group; and

- p is 1 or 2 and the carbamate group is attached at positions 2, 3 or 4 of the azabicyclic ring;

wherein when

- p is 2;

- the carbamate group is attached at position 3 of the azabicyclic ring; and

- R1 is a phenyl group, which is optionally substituted with one or two, identical or different, substituents chosen from chlorine, fluorine, bromine, methyl, hydroxy and cyano;

then R2 cannot be one of: unsubstituted cyclopropylmethyl; unsubstituted cyclobutylmethyl; unsubstituted cyclopentylmethyl; cyclohexylmethyl optionally


substituted with a methyl or an isopropenyl group; unsubstituted cyclohexenyl;  
unsubstituted norbornenyl; unsubstituted bicyclo[2.2.1]heptanyl; unsubstituted  
benzo[1,3]dioxolyl; unsubstituted 2,3-dihydrobenzo[1,4]dioxinyl; unsubstituted  
benzyl; a benzyl group which is substituted with one or two, identical or different,  
substituents chosen from fluorine, chlorine, bromine, methoxy, methyl,  
trifluoromethyl, ethyl, tertbutyl, hydroxy, hydroxymethyl, cyano, aminocarbonyl,  
trifluoromethoxy, benzyloxy, and isopropoxy; or a benzyl group which is  
substituted with three fluorine atoms;

or a pharmaceutically acceptable salt thereof or a stereoisomer thereof

with the proviso that the compound of formula (I) is not one of

- Diphenylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester<sub>1</sub> or
- Ethylphenylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester<sub>1</sub>
- Quinuclidin-3-yl benzo[d][1,3]dioxol-5-ylmethyl(phenyl)carbamate, or
- Quinuclidin-3-yl (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl(m-tolyl)carbamate.

37. (Currently Amended) A compound of formula (II)



wherein

- R1 represents a group chosen from phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, benzyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl, and thiophen-3-ylmethyl;

- R2 represents a group chosen from optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated cycloalkylmethyl, phenyl, benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl, thiophen-3-ylmethyl, pyridyl, and pyridylmethyl; wherein the carbocyclic moieties in the cycloalkyl, cycloalkylmethyl, phenyl, benzyl or phenethyl groups are optionally bridged or fused to another saturated, unsaturated or aromatic carbocyclic moiety or to a cyclic moiety comprising carbon atoms and 1 or 2 oxygen atoms;

wherein the cyclic groups present in R1 and R2 are optionally substituted by one, two or three, which may be identical or different, substituents chosen from halogen; straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower alkoxy; -SH; straight or branched optionally substituted lower alkylthio; nitro; cyano;  $-NR'R''$ ,  $-CO_2R'$ ,  $-C(O)-NR'R''$ ,  $-N(R''')C(O)-R'$ , and  $-N(R''')-C(O)NR'R''$  groups, wherein  $R'$ ,  $R''$  and  $R'''$ , which may be identical or different, are each independently chosen from a hydrogen atom and a straight or branched, optionally substituted lower alkyl group, or  $R'$  and  $R''$  together with the atom to which they are attached form a cyclic group;

- p is 1 or 2 and the carbamate group is attached at positions 2, 3 or 4 of the azabicyclic ring;

- m is an integer ranging from 0 to 8;

- n is an integer ranging from 0 to 4;

- A represents a group chosen from -CH<sub>2</sub>-; -CH=CR'-; -CR'=CH-; -CR'R''-; -C(O)-, -O-, -S-, -S(O)-, -S(O)<sub>2</sub>- and -NR'-, wherein R' and R'', which may be identical or different, are each independently chosen from a hydrogen atom and a straight or branched, optionally substituted lower alkyl group, or R' and R'' together with the atom to which they are attached form a cyclic group;

- B represents a hydrogen atom, or a group chosen from straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower alkoxy; cyano; nitro; -CH=CR'R''; -C(O)OR'; -OC(O)R'; -SC(O)R'; -C(O)NR'R''; -NR'C(O)OR''; -NR'C(O)NR''; cycloalkyl; phenyl; naphthanelyl; 5,6,7,8-tetrahydronaphthanelyl; benzo[1,3]dioxolyl; heteroaryl; and heterocyclyl; wherein R' and R'', which may be identical or different, are each independently chosen from a hydrogen atom and a straight or branched, optionally substituted lower alkyl group, or R' and R'' together with the atom to which they are attached form a cyclic group; and

wherein the cyclic groups represented by B are optionally substituted by one, two or three, identical or different, substituents chosen from halogen; hydroxy; straight or branched, optionally substituted lower alkyl; phenyl; -OR'; -SR'; -NR'R''; -NHCOR'; -CONR'R''; -CN; -NO<sub>2</sub>; and -COOR'; wherein R' and R'' are each independently chosen from a hydrogen atom, or a straight or branched, optionally substituted lower alkyl group, or R' and R'' together with the atom to which they are attached form a cyclic group; and

-  $X^-$  represents a pharmaceutically acceptable anion of a mono or polyvalent acid;

wherein when

- p is 2;

- the carbamate group is attached at position 3 of the azoniabicyclic ring having (3R)-configuration;


- R1 is a phenyl group which is optionally substituted with a fluorine atom or a methyl group;

- R2 is an unsubstituted cyclohexylmethyl group or a benzyl group which is optionally substituted with one or three fluorine atoms; and

-  $X^-$  is iodine;

then, the sequence  $B-(CH_2)_n-A-(CH_2)_m-$  cannot be a methyl group;

or a stereoisomer thereof; or a mixture of stereoisomers thereof, or a mixture of at least one stereoisomer of a compound of formula (II) and at least one stereoisomer of a compound of formula (I)



(I)

38. (Currently Amended) The compound of Claim 36, wherein when the cyclic group present in R1 is unsubstituted or has only one ~~substituent~~substituent, R2 has at least one substituent.

39. (Previously Presented) The compound of Claim 36 wherein when R2 is not substituted, the cyclic group present in R1 has at least two substituents.

40. (Currently Amended) The compound of Claim 36, wherein when p is 2;

the carbamate group is attached at position 3 of the azabicyclic ring;

and R1 is an unsubstituted indanyl group ~~or a phenyl group, which is optionally substituted with one or two, identical or different, substituents chosen from chlorine, fluorine, bromine, methyl, hydroxy and cyano;~~

then R2 cannot be one of: unsubstituted cyclopropylmethyl; unsubstituted cyclobutylmethyl; unsubstituted cyclopentylmethyl; cyclohexylmethyl optionally substituted with a methyl or an isopropenyl group; unsubstituted cyclohexenyl; unsubstituted norbornenyl; unsubstituted ~~bicyclo~~bicyclo[2,2,1]heptanyl; unsubstituted benzo[1,3]dioxolyl; unsubstituted 2,3-dihydrobenzo[1,4]dioxinyl; unsubstituted benzyl; a benzyl group which is substituted with one or two, identical or different, substituents chosen from fluorine, chlorine, bromine, methoxy, methyl, trifluoromethyl, ethyl, tertbutyl, hydroxy, hydroxymethyl, cyano, aminocarbonyl, trifluoromethoxy, benzyloxy, and isopropoxy; or a benzyl group which is substituted with three fluorine atoms.

41. (Previously Presented) The compound of Claim 36, wherein R1 represents a group chosen from 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, benzyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl; and thiophen-3-ylmethyl;

wherein the cyclic group present in R1 is optionally substituted by one, two, or three, identical or different, substituents chosen from halogen; straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower alkoxy; -SH; straight or branched optionally substituted lower alkylthio; nitro; cyano; -NR'R"; -CO<sub>2</sub>R'; -C(O)-NR'R"; -N(R''')C(O)-R'; and -N(R''')-C(O)NR'R";

wherein R', R" and R''' each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R" together with the atom to which they are attached form a cyclic group.

42. (Previously Presented) The compound of Claim 36, wherein R2 represents an optionally substituted group chosen from lower alkyl, lower alkenyl, lower alkynyl, saturated or unsaturated cycloalkyl, phenyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl, thiophen-3-ylmethyl, pyridyl, pyridylmethyl, and a saturated or unsaturated cycloalkylmethyl which has at least one substituent and is chosen from substituted cyclopropylmethyl, substituted cyclobutylmethyl and substituted cyclopentylmethyl;

wherein the substituents of the cyclic group present in R2 are one, two or three, identical or different, substituents chosen from halogen; straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower

alkoxy; -SH; straight or branched optionally substituted lower alkylthio; nitro; cyano; —NR'R"; -CO<sub>2</sub>R'; -C(O)-NR'R"; —N(R'')C(O)-R'; and -N(R'')-C(O)NR'R";

wherein R', R'' and R''' each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R'' together with the atom to which they are attached form a cyclic group.

43. (Canceled)

44. (Previously Presented) The compound of Claim 37, wherein the compound is not one of:

- (3R)-3-(Benzylphenylcarbamoyloxy)-1-methyl-1-azoniabicyclo[2.2.2]octane iodide;
- (3R)-3-[(4-Fluorobenzyl)phenylcarbamoyloxy]-1-methyl-1-azoniabicyclo[2.2.2]octane iodide;
- (3R)-3-(Benzyl-o-tolylcarbamoyloxy)-1-methyl-1-azoniabicyclo[2.2.2]octane iodide
- (3R)-1-Methyl-3-[o-tolyl-(2,4,5-trifluorobenzyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane iodide;
- (3R)-3-[(4-Fluorobenzyl)-m-tolylcarbamoyloxy]-1-methyl-1-azoniabicyclo[2.2.2]octane iodide;
- (3R)-3-[Benzyl-(2-fluorophenyl)carbamoyloxy]-1-methyl-1-azoniabicyclo[2.2.2]octane iodide; or
- (3R)-3-[Cyclohexylmethyl-(2-fluorophenyl)carbamoyloxy]-1-methyl-1-azoniabicyclo[2.2.2]octane iodide.

45. (Previously Presented) The compound of Claim 37, wherein R1 represents a group chosen from phenyl, 2-thienyl, 3-thienyl, thiophen-2-ylmethyl, thiophen-3-ylmethyl, furan-2-ylmethyl, and furan-3-ylmethyl, wherein the cyclic group present in R1 is optionally substituted with one, two, or three, identical or different, substituents chosen from fluorine, chlorine, bromine, methyl, methoxy, trifluoromethyl, ethyl, tert-butyl, hydroxy, and cyano.

46. (Previously Presented) The compound of Claim 45, wherein R1 represents a group chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methylphenyl, 4-methylphenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,4,5-trifluorophenyl, 5-methylfuran-2-ylmethyl, 4-fluoro-2-methylphenyl, 3-fluoro-4-methoxyphenyl, 3-methyl-thiophen-2-ylmethyl, 4,5-dimethyl-thiophen-2-ylmethyl, thiophen-3-ylmethyl, 5-methyl-furan-2-ylmethyl, 5-methyl-2-trifluoromethyl-furan-3-ylmethyl, and 2, 5-dimethyl-furan-3-ylmethyl.

47. (Previously Presented) The compound of Claim 37, wherein R2 represents a group chosen from pent-4-enyl, pentyl, butyl, allyl, benzyl, thiophen-2-ylmethyl, thiophen-3-ylmethyl, furan-2-ylmethyl, furan-3-ylmethyl, phenethyl, cyclopentyl, cyclohexyl, and cyclohexylmethyl, wherein the cyclic group present in R2 is optionally substituted with one, two, or three, identical or different, substituents chosen from fluorine, chlorine, bromine, methyl, methoxy, trifluoromethyl, ethyl, tert-butyl, hydroxy, and cyano.

48. (Previously Presented) The compound of Claim 47, wherein R<sub>2</sub> represents a group chosen from 3-fluorobenzyl, 2,4,5-trifluorobenzyl, 3,4,5-trifluorobenzyl, 5-bromothiophen-2-ylmethyl, 3,4-dimethoxyphenylethyl, 3-methylthiophen-2-ylmethyl, thiophen-3-ylmethyl, 4-bromo-5-methylthiophen-2-ylmethyl, 4,5-dimethylfuran-2-ylmethyl, furan-3-ylmethyl, 2-fluoro-4-methoxybenzyl, 2-(4-fluorophenyl)ethyl, butyl, pent-4-enyl, and cyclopentyl.

49. (Previously Presented) The compound of Claim 37, wherein

- A is —CH<sub>2</sub>—;
- m and n are both 0;
- B represents a group chosen from straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower alkoxy; cyano; nitro; -CH=CR'R"; -C(O)OR'; -OC(O)R; -SC(O)R'; -C(O)NR'R"; -NR'C(O)OR"; -NR'C(O)NR"; cycloalkyl; phenyl; naphthanelyl; 5,6,7,8-tetrahydronaphthanelyl; benzo[1,3]dioxolyl; heteroaryl; and heterocyclyl; and
- R' and R" are each independently chosen from a hydrogen atom and a straight or branched, optionally substituted lower alkyl group, or R' and R" together with the atom to which they are attached form a cyclic group;

and wherein the cyclic groups represented by B are optionally substituted by one, two or three, identical or different, substituents chosen from halogen; hydroxyl; straight or branched, optionally substituted lower alkyl; phenyl; -OR'; -SR'; -NR'R"; -NHCOR'; -CONR'R"; -CN, -NO<sub>2</sub> and -COOR'; wherein R' and R" are each independently chosen

from a hydrogen atom, or a straight or branched, optionally substituted lower alkyl group, or R' and R" together with the atom to which they are attached form a cyclic group.

50. (Previously Presented) The compound of Claim 37, wherein

- A is  $\text{—CH}_2\text{—}$ ;

- B represents a hydrogen atom, or a group chosen from straight or branched, optionally substituted lower alkyl; hydroxy; straight or branched, optionally substituted lower alkoxy; cyano; nitro;  $\text{—CH=CR'R''}$ ;  $\text{—C(O)OR'}$ ;  $\text{—OC(O)R'}$ ;  $\text{—SC(O)R'}$ ;  $\text{—C(O)NR'R''}$ ;  $\text{—NR'C(O)OR''}$ ;  $\text{—NR'C(O)NR''}$ ; cycloalkyl; phenyl; naphthanelyl; 5,6,7,8-tetrahydronaphthanelyl; benzo[1,3]dioxolyl; heteroaryl; and heterocyclyl;

wherein R' and R" are each independently chosen from a hydrogen atom and a straight or branched, optionally substituted lower alkyl group, or R' and R" together with the atom to which they are attached form a cyclic group;

and wherein the cyclic group represented by B is optionally substituted by one, two or three, identical or different, substituents chosen from halogen; hydroxy; straight or branched, optionally substituted lower alkyl; phenyl;  $\text{—OR'}$ ;  $\text{—SR'}$ ;  $\text{—NR'R''}$ ;  $\text{—NHCOR'}$ ;  $\text{—CONR'R''}$ ;  $\text{—CN}$ ;  $\text{—NO}_2$ ; and  $\text{—COOR'}$ ; wherein R' and R" are each independently chosen from a hydrogen atom, or a straight or branched, optionally substituted lower alkyl group, or R' and R" together with the atom to which they are attached form a cyclic group; and

- at least one of m or n is not 0.

51. (Previously Presented) The compound of Claim 37, wherein B represents a thiophen-2-yl group or a phenyl group which is optionally substituted with one, two, or three, identical or different, substituents chosen from halogen atoms and hydroxy, methyl, -CH<sub>2</sub>OH, -OMe, -NMe<sub>2</sub>, -NHCOMe, -CONH<sub>2</sub>, -CN, -NO<sub>2</sub>, -COOMe, and -CF<sub>3</sub> groups.

52. (Previously Presented) The compound of Claim 51, wherein B represents a group chosen from phenyl, 4-fluorophenyl, 3-hydroxyphenyl, and thiophen-2-yl.

53. (Previously Presented) The compound of Claim 37, wherein n= 0 or 1; m is an integer ranging from 1 to 6; and A represents a group chosen from -CH<sub>2</sub>-, -CH=CH-, -CO-, -NMe-, -O-, and -S-.

54. (Previously Presented) The compound of Claim 53, wherein m is an integer equal to 1, 2 or 3 and A represents a group chosen from -CH<sub>2</sub>-, -CH=CH-, and -O-.

55. (Previously Presented) The compound of Claim 37, wherein B-(CH<sub>2</sub>)<sub>n</sub>-A-(CH<sub>2</sub>)<sub>m</sub>- represents a group chosen from 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 3-phenylpropyl, 3-(3-hydroxyphenoxy)propyl, 3-(4-fluorophenoxy)propyl, 3-thiophen-2-ylpropyl, allyl, heptyl, 3-cyanopropyl, and methyl.

56. (Previously Presented) The compound of Claim 37, wherein X<sup>-</sup> represents anion chosen from chloride, bromide, trifluoroacetate, and methanesulphonate.

57. (Previously Presented) The compound of Claim 36, wherein p is 2.

58. (Previously Presented) The compound of Claim 36, wherein the azabicyclic ring is substituted in the 3-position.

59. (Previously Presented) The compound of Claim 58, wherein the carbon at the 3-position of the azabicyclic ring has R configuration.

60. (Previously Presented) The compound of Claim 58, wherein the carbon at the 3-position of the azabicyclic ring has S configuration.

61. (Previously Presented) The compound of Claim 36, wherein the compound of formula (I) is a single isomer.

62. (Previously Presented) The compound of Claim 36, chosen from:

- [2-(3,4-Dimethoxyphenyl)ethyl]-(5-methylfuran-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- (5-Bromothiophen-2-ylmethyl)-(2,4,5-trifluorophenyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- (4-Fluoro-2-methylphenyl)-(3-methylthiophen-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;

- (3-Fluoro-4-methoxyphenyl)thiophen-3-ylmethylcarbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester
- Thiophen-3-ylmethyl-(2,4,5-trifluorobenzyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- (4-Bromo-5-methylthiophen-2-ylmethyl)-(3-methylthiophen-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- (4, 5-Dimethylfuran-2-ylmethyl)-(5-methylfuran-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- Furan-3-ylmethyl-(5-methyl-2-trifluoromethylfuran-3-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- (2,5-Dimethylfuran-3-ylmethyl)-(2-fluoro-4-methoxybenzyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- [2-(4-Fluorophenyl)ethyl]-(3-methylthiophen-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- Butyl-(2, 5-difluorophenyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester;
- (2,6-Difluorophenyl)pent-4-enylcarbamic acid (3R)-1-aza-bicyclo[2.2.2]oct-3-yl ester;
- Cyclopentyl-(4,5-dimethylthiophen-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester; and
- (5-Ethylthiophen-2-ylmethyl)-(3-methylthiophen-2-ylmethyl)carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester.

63. (Previously Presented) The compound of Claim 36, chosen from:

- (3R)-3-[(3-Fluorobenzyl)-(3-fluorophenyl)carbamoyloxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-[(3-Fluorobenzyl)-(3-fluorophenyl)carbamoyloxy]-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-(2-Phenoxyethyl)-3-[m-tolyl-(2,4,5-trifluorobenzyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-(3-Phenylpropyl)-3-[m-tolyl-(2,4,5-trifluorobenzyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-[(3-Fluorophenyl)-(3,4,5-trifluorobenzyl)carbamoyloxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-Allyl-3-[[2-(3,4-dimethoxyphenyl)ethyl]-(5-methylfuran-2-ylmethyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-[(5-Bromothiophen-2-ylmethyl)-(2,4,5-trifluorophenyl)carbamoyloxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[[2-(3,4-dimethoxyphenyl)ethyl]-(5-methylfuran-2-ylmethyl)carbamoyloxy]-1-(4-ethoxycarbonylbutyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[(4-Fluoro-2-methylphenyl)-(3-methylthiophen-2-ylmethyl)carbamoyloxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[(3-Fluoro-4-methoxyphenyl)thiophen-3-ylmethylcarbamoyloxy]-1-(3-phenylallyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-1-Phenethyl-3-[thiophen-3-ylmethyl-(2,4,5-trifluorobenzyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;

- (3R)-3-[(4-Bromo-5-methylthiophen-2-ylmethyl)-(3-methylthiophen-2-ylmethyl)carbamoyloxy]-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[(4,5-Dimethylfuran-2-ylmethyl)-(5-methylfuran-2-ylmethyl)carbamoyloxy]-1-[3-(3-hydroxyphenoxy)propyl]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-1-[3-(4-Fluorophenoxy)propyl]-3-[furan-3-ylmethyl-(5-methyl-2-trifluoromethylfuran-3-ylmethyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[(2,5-Dimethylfuran-3-ylmethyl)-(2-fluoro-4-methoxybenzyl)carbamoyloxy]-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-1-Allyl-3-[2-(4-fluorophenyl)ethyl]-(3-methylthiophen-2-ylmethyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[Butyl-(2,5-difluorophenyl)carbamoyloxy]-1-heptyl-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-1-(3-cyanopropyl)-3-[(2,6-difluorophenyl)pent-4-enylcarbamoyloxy]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[Cyclopentyl-(4,5-dimethylthiophen-2-ylmethyl)carbamoyloxy]-1-methyl-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-[(3-Fluorophenyl)-(3,4,5-trifluorobenzyl)carbamoyloxy]-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-[(5-Ethylthiophen-2-ylmethyl)-(3-methylthiophen-2-ylmethyl)carbamoyloxy]-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide;

- (3R)-3-[[2-(3,4-dimethoxyphenyl)ethyl]-(5-methylfuran-2-ylmethyl)carbamoyloxy]-1-(4-ethoxycarbonylbutyl)-1-azoniabicyclo[2.2.2]octane formate;
- (3R)-3-[(4-Fluoro-2-methylphenyl)-(3-methylthiophen-2-ylmethyl)carbamoyloxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-[(3-Fluoro-4-methoxyphenyl)thiophen-3-ylmethylcarbamoyloxy]-1-(3-phenylallyl)-1-azoniabicyclo[2.2.2]octane bromide; and
- (3R)-1-Allyl-3-[2-(4-fluorophenyl)ethyl]-(3-methylthiophen-2-ylmethyl)carbamoyloxy]-1-azoniabicyclo[2.2.2]octane bromide.

64. (Previously Presented) A pharmaceutical composition comprising at least one compound of Claim 36, and at least one pharmaceutically acceptable carrier or diluent.

65. (Canceled)

66. (Previously Presented) A method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of M3 muscarinic receptors, comprising administering to said subject an effective amount of at least one compound of Claim 36.

67. (Previously Presented) The method according to Claim 66, wherein the pathological condition is chosen from respiratory, urological, and gastrointestinal disease or disorder.

68. (Previously Presented) A combination product comprising,  
(i) at least one first compound of Claim 36; and  
(ii) at least one second compound effective in the treatment of at least one pathological condition chosen from respiratory, urological, and gastrointestinal disease or disorder, wherein the at least one first compound and the at least one second compound are administered simultaneously, separately, or sequentially.

69. (Previously Presented) A combination product comprising,  
(i) at least one first compound of Claim 36; and  
(ii) at least one second compound chosen from a  $\beta_2$  agonist, steroid, antiallergic drug, phosphodiesterase IV inhibitor, and a leukotriene D4 (LTD4) antagonist, wherein the at least one first compound and the at least one second compound are administered simultaneously, separately, or sequentially in the treatment of a respiratory disease.

70-79. (Canceled)